p.7 抽出テキスト

MASTER DAPT Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen MATRIX Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of angioX MCS Mechanical circulatory support MD Maintenance dose MI Myocardial infarction MINOCA Myocardial infarction with non-obstructive coronary arteries MRA Mineralocorticoid receptor antagonist MVD Multivessel disease MVO Microvascular obstruction NOAC Non-vitamin K antagonist oral anticoagulant NORSTENT Norwegian Coronary Stent Trial NPV Negative predictive value NRT Nicotine replacement therapy NSTE Non-ST elevation NSTE-ACS Non-ST elevation acute coronary syndrome NSTEMI Non-ST-elevation myocardial infarction NT-pro BNP N-terminal pro B-type natriuretic peptide NYHA New York Heart Association o.d. Once a day OAC Oral anticoagulant/ation OASIS-5 Fifth Organization to Assess Strategies in Acute Ischemic Syndromes OASIS-6 The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction OAT Occluded Artery Trial OCT Optical coherence tomography ODYSSEY OUTCOMES

Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab OHCA Out-of-hospital cardiac arrest OR Odds ratio PARADISE-MI Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI PCI Percutaneous coronary intervention PCSK9 Proprotein convertase subtilisin/kexin type 9 PE Pulmonary embolism PEGASUS-TIMI 54 PrEvention with TicaGrelor of SecondAry Thrombotic Events in High-RiSk Patients with Prior AcUte Coronary Syndrome— Thrombolysis In Myocardial Infarction PEPCAD NSTEMI Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction PLATO PLATelet inhibition and patient Outcomes POC Point of care POPular Genetics Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment PPCI Primary percutaneous coronary intervention PPI Proton pump inhibitor PPV Positive predictive value PRAMI Preventive Angioplasty in Myocardial Infarction PREM Patient-reported experience measure PROM Patient-reported outcome measure QI Quality indicator RAAS Renin–angiotensin–aldosterone system RAPID-CTCA Rapid Assessment of Potential Ischaemic heart Disease with CTCA RCT Randomized controlled trial REALITY Restrictive and Liberal Transfusion Strategies in Patients With Acute Myocardial Infarction REBOOT-CNIC TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion REDUCE-SWEDE- HEART

Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry REMINDER Double-Blind, Randomized, Placebo-Controlled Trial Evaluating The Safety And Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial Infarction REVELATION REVascularization With PaclitaxEL-Coated Balloon Angioplasty Versus Drug-Eluting Stenting in Acute Myocardial InfarcTION RIVAL RadIal Vs femorAL access for coronary intervention ROMICAT II Multicenter Study to Rule Out Myocardial Infarction by Cardiac Computed Tomography ROSC Return of spontaneous circulation RR Relative risk RV Right ventricular SAPT Single antiplatelet therapy SBP Systolic blood pressure s.c. Subcutaneous SCAD Spontaneous coronary artery dissection SHOCK Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock SGLT2 Sodium–glucose co-transporter 2 SMART-DECISION Long-term Beta-blocker Therapy After Acute Myocardial Infarction SPECT Single-photon emission computerized tomography STE ST elevation STEMI ST-elevation myocardial infarction STOPDAPT-2-ACS ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS STREAM Strategic Reperfusion Early After Myocardial Infarction SWEDEHEART Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies TALOS-AMI TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction TAT Triple antithrombotic therapy Downloaded from academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 07 October 2026